191 related articles for article (PubMed ID: 22080337)
21. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data.
Du X; Goodwin JS
J Clin Oncol; 2001 Mar; 19(5):1455-61. PubMed ID: 11230491
[TBL] [Abstract][Full Text] [Related]
22. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA
J Natl Cancer Inst; 2005 Jul; 97(14):1080-3. PubMed ID: 16030306
[TBL] [Abstract][Full Text] [Related]
23. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
[TBL] [Abstract][Full Text] [Related]
24. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.
Du XL; Key CR; Dickie L; Darling R; Geraci JM; Zhang D
Med Care; 2006 Feb; 44(2):124-31. PubMed ID: 16434911
[TBL] [Abstract][Full Text] [Related]
25. Factors Influencing Receipt of Interventional Pain Management Among Medicaid Beneficiaries with Cancer.
Halpern MT; Fiero MH
Pain Physician; 2019 May; 22(3):E147-E155. PubMed ID: 31151338
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database.
Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM
Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Oncology Practice Billing Claims for Supplementing Chemotherapy: A Pilot Study in the Georgia SEER Cancer Registry.
Howlader N; Ward KC; Warren JL; Campbell DS; Coyle L; Mariotto AB
J Natl Cancer Inst Monogr; 2020 May; 2020(55):82-88. PubMed ID: 32412070
[TBL] [Abstract][Full Text] [Related]
28. Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data.
Lavery JA; Lipitz-Snyderman A; Li DG; Bach PB; Panageas KS
JCO Clin Cancer Inform; 2019 Feb; 3():1-24. PubMed ID: 30715928
[TBL] [Abstract][Full Text] [Related]
29. Geographic variation in physicians' responses to a reimbursement change.
Jacobson M; Earle CC; Newhouse JP
N Engl J Med; 2011 Dec; 365(22):2049-52. PubMed ID: 22047517
[No Abstract] [Full Text] [Related]
30. External validation of a claims-based algorithm for classifying kidney-cancer surgeries.
Miller DC; Saigal CS; Warren JL; Leventhal M; Deapen D; Banerjee M; Lai J; Hanley J; Litwin MS
BMC Health Serv Res; 2009 Jun; 9():92. PubMed ID: 19500395
[TBL] [Abstract][Full Text] [Related]
31. Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches.
Brooks GA; Bergquist SL; Landrum MB; Rose S; Keating NL
JCO Clin Cancer Inform; 2019 May; 3():1-19. PubMed ID: 31070985
[TBL] [Abstract][Full Text] [Related]
32. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
33. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.
Schrag D; Gelfand SE; Bach PB; Guillem J; Minsky BD; Begg CB
J Clin Oncol; 2001 Sep; 19(17):3712-8. PubMed ID: 11533092
[TBL] [Abstract][Full Text] [Related]
34. Physician response to financial incentives when choosing drugs to treat breast cancer.
Epstein AJ; Johnson SJ
Int J Health Care Finance Econ; 2012 Dec; 12(4):285-302. PubMed ID: 23124970
[TBL] [Abstract][Full Text] [Related]
35. Information gained from linking SEER Cancer Registry Data to state-level hospital discharge abstracts. Surveillance, Epidemiology, and End Results.
Brooks JM; Chrischilles E; Scott S; Ritho J; Chen-Hardee S
Med Care; 2000 Nov; 38(11):1131-40. PubMed ID: 11078053
[TBL] [Abstract][Full Text] [Related]
36. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA;
Med Care; 2008 Mar; 46(3):303-8. PubMed ID: 18388845
[TBL] [Abstract][Full Text] [Related]
37. Poststroke rehabilitation in older Americans. The Medicare experience.
Lee AJ; Huber J; Stason WB
Med Care; 1996 Aug; 34(8):811-25. PubMed ID: 8709662
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service.
Schenck AP; Klabunde CN; Warren JL; Peacock S; Davis WW; Hawley ST; Pignone M; Ransohoff DF
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):799-804. PubMed ID: 18381471
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.
Gilden DM; Kubisiak JM; Pohl GM; Ball DE; Gilden DE; John WJ; Wetmore S; Winfree KB
J Med Econ; 2017 Feb; 20(2):151-161. PubMed ID: 27574722
[TBL] [Abstract][Full Text] [Related]
40. Does publishing the parameters that trigger review of Medicare claims change provider behavior? Results of the parameter release study.
Nyman JA; Akhtar MR; Feldman R
Med Care; 1995 Oct; 33(10):1022-34. PubMed ID: 7475401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
